7月31日，10x Genomics盘中上涨5.05%，报48.66美元/股，成交额5064.2万美元。
消息面上，公司即将于8月6日盘后发布季度财报，市场一致预期本季度营收约1.47亿美元，同比增长5.28%，调整后每股亏损预计收窄至-0.24美元，同比改善34.45%。此前一季度公司EPS为-0.10美元，大幅优于市场预期的-0.30美元，营收亦超预期，奠定乐观基调。
此外，公司近期接连与洛桑大学医院、克利夫兰诊所达成合作，推进单细胞与空间技术在癌症诊断领域应用，并完成对Proteintech Genomics的收购以拓展蛋白组学能力。BofA Securities于7月将目标价由30美元大幅上调至46美元，机构观点整体偏多。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.